HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease.
about
Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologiesNon-invasive diagnosis of liver fibrosis in chronic hepatitis CAlcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infectionsCocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort studyChallenges in the treatment of HIV and HCV coinfection.The Impact of Sparse Follow-up on Marginal Structural Models for Time-to-Event Data.Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts.Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients.Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients?Elevated aspartate aminotransferase-to-platelet ratio index in perinatally HIV-infected children in the United StatesImpact of HIV on liver fibrosis in men with hepatitis C infection and haemophilia.Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients.HCV and HIV co-infection: mechanisms and management.Improving noninvasive methods of assessing liver fibrosis in patients with hepatitis C virus/human immunodeficiency virus co-infection.Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection--The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index.HIV monoinfection is associated with increased aspartate aminotransferase-to-platelet ratio index, a surrogate marker for hepatic fibrosisElevated AST-to-platelet ratio index is associated with increased all-cause mortality among HIV-infected adults in Zambia.Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected Persons.The insulin-like growth factor axis and risk of liver disease in hepatitis C virus/HIV-co-infected women.Use of the AST to platelet ratio index in HCV/HIV co-infected patients.Combination Antiretroviral Therapy Is Associated With Reduction in Liver Fibrosis Scores in HIV-1-Infected Subjects.Is YKL-40 a new therapeutic target in cancer?Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virusSystematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection.Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort.Impact of lifetime alcohol use on liver fibrosis in a population of HIV-infected patients with and without hepatitis C coinfection.Assessment of liver disease (noninvasive methods)YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?Prevalence and predictors of elevated aspartate aminotransferase-to-platelet ratio index in Latin American perinatally HIV-infected children.Prediction of fibrosis in hepatitis C patients: assessment using hydroxyproline and oxidative stress biomarkers.Plasma YKL-40: a potential new cancer biomarker?Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients.Non-invasive assessment of liver fibrosis: it is time for laboratory medicine.Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis.Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection.Correcting for Measurement Error in Time-Varying Covariates in Marginal Structural Models.Opioid use and risk of liver fibrosis in HIV/hepatitis C virus-coinfected patients in Canada.Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study.[Evaluation of APRI score in liver disease following the introduction of antiretroviral therapy in HIV and HCV coinfected versus HIV monoinfected patients].
P2860
Q26752723-B9C9FF93-EFEC-4BC6-ADDF-263223C4EE69Q26865956-A3B1143F-66C6-433E-9F58-F138A2FF4F6BQ28070280-1EB03044-F157-4000-9BDD-CB92BD0CD3D6Q28468297-5D2FB727-B8C9-440E-9428-13EF63B78FFAQ30389282-E88BDA85-0647-4817-BB75-79B982BF0C30Q31026915-3498DD7E-9A6A-4CE6-97B5-03725BF82058Q33410098-B33B2AEC-594A-4DE4-9697-96EE9707677EQ33577482-241C1E6A-7F61-4831-8062-2B003033BE84Q33665359-76F33264-A1F7-4E5E-B4A7-64EB8F65E88CQ34200171-D5B4EABD-1A2B-4F51-8684-39F5FC83E960Q34345002-7D4A48CC-45FC-449D-9684-51A4B93C4487Q34749550-4B342DEB-44B0-4F72-AC14-78B27AF5C2D4Q35090634-DDC886E9-D352-48A9-AEA7-65327703EEA1Q35176164-A0622A02-EACB-40AE-BBCE-7CE5D4533170Q35668307-6F3841AB-90ED-4C0C-83B4-94743A47E605Q35766031-88E07E46-9C23-471B-BBED-1DC551BDAA0DQ35772764-9040960B-378C-4DE8-B134-C098EA34B956Q36402487-53AC30FD-4F32-44D3-9D34-3FBD3591D766Q36426596-17947C76-81B1-4C28-8AF4-11A1D5B98D0DQ36555228-F49A056A-C7BC-41D8-9417-29555B88A044Q36566930-4FFE5A96-A005-4AE3-9666-825240D94AFDQ36709555-07234F20-38CB-497D-AD4D-F0C505724733Q37037079-2ACEDB57-841F-429E-8227-C46C70203D87Q37063803-B908B726-11E9-45ED-BC82-E097268849F3Q37122490-8CCC414F-8851-4478-AD8B-CF0D22675DDAQ37124502-416B17E5-96D7-45D1-AE38-05D85351D629Q37135387-447D2F65-4B18-4397-B66E-CE1BC0E5E7E4Q37199708-6013D9C0-A9AD-480F-B29D-D6A6265E5954Q37334247-CEA66B31-0BA6-4249-A3E2-30C078A672A4Q37420263-AC5181B2-772C-4737-982D-2AEAB7987751Q37468027-BAE9C8AD-80C1-4238-96CC-702212DFD8DBQ37605869-C6003EC0-B4D1-4588-9F71-A697C7B8C3E2Q37726058-53B095A1-9382-4E4F-9CB4-65A13BD6B111Q37801658-36AB89AF-26DD-4F34-B243-1AB9C511FC99Q37841383-7BF0F6F2-664F-4C40-9C33-0144377FC1DAQ39244103-79F80B35-D9B2-4595-A839-5F9AE3744B57Q39601889-9FD5E515-E441-40F3-9716-E237EEC05D04Q40770942-14DC8A3F-818A-45C8-A962-B0704749C04AQ40942161-444DCBDF-E97B-459C-B1A5-BF5B66069DA3Q42772515-16E4B0E1-1199-4D96-959E-B85D245E2C8A
P2860
HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
HIV infection does not affect ...... C virus-related liver disease.
@ast
HIV infection does not affect ...... C virus-related liver disease.
@en
type
label
HIV infection does not affect ...... C virus-related liver disease.
@ast
HIV infection does not affect ...... C virus-related liver disease.
@en
prefLabel
HIV infection does not affect ...... C virus-related liver disease.
@ast
HIV infection does not affect ...... C virus-related liver disease.
@en
P2093
P50
P1476
HIV infection does not affect ...... C virus-related liver disease.
@en
P2093
C Robert Horsburgh
Camilla Graham
Catherine Fleming
Donald E Craven
Margaret Koziel
Sheila Tumilty
Sheri Stuver
P304
P356
10.1097/01.QAI.0000184856.31695.BF
P407
P577
2005-12-01T00:00:00Z